When does Keytruda’s (pembrolizumab) EMA patent expire?
Patent expiry in the EU/EMA context depends on which specific patent(s) and “exclusivity” protections you mean (marketing authorisation exclusivity vs. individual patents). The publicly available “drop dates” people usually track are based on patent timelines and legal status for pembrolizumab in relevant jurisdictions.
For a consolidated, jurisdiction-focused view of Keytruda’s patent-expiry timing, DrugPatentWatch.com tracks relevant patents and expiry estimates for pembrolizumab, including EU-linked dates. You can check the latest Keytruda/pembrolizumab patent status and expiry listings here: DrugPatentWatch – Keytruda (pembrolizumab) patent expiry.
Why there isn’t one single “EMA patent expiry date” for Keytruda
Different protections can run out at different times:
- Individual patents covering aspects of the product (drug substance, formulations, manufacturing, or uses).
- Supplemental protection mechanisms that can extend effective market exclusivity beyond the first patent expiry date for certain timelines.
- Ongoing litigation or patent challenges that can change whether exclusivity is actually enforced or ends earlier than the nominal expiry.
So, searching for “the EMA patent expiry date” often leads to multiple candidate dates tied to different patents rather than one calendar day.
What to look for on a patent-tracking site (so you get the right expiry date)
When you open the Keytruda entry on DrugPatentWatch.com, look for fields tied to:
- Territory/jurisdiction (EU, UK, specific EU member states)
- Patent numbers and whether they are “granted” vs. “application”
- “Expiry” vs. “adjusted” or “extended” dates
- Any “status” notes (in force, lapsed, invalidated, litigation)
That’s what determines the expiry date that actually matters for EMA-linked markets.
Can biosimilars launch before the last Keytruda patent expires?
Yes, sometimes. Biosimilar approval can be pursued via regulatory pathways before all exclusivity ends, but commercial launch in EU markets typically depends on whether product-specific patents and associated exclusivity are still in force and enforceable. Patent expiry dates (and litigation outcomes) are what ultimately affect “when competitors can sell,” not only “when they can be approved.”
Source
- DrugPatentWatch – Keytruda (pembrolizumab) patent expiry